In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved   Roots Analysis has announced the addition of the (Avastin) Bevacizumab Biosimilars – Pipeline Review and Partnerships”...